Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950076 · ClinicalTrials.gov registry record · Phase 4
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
A Phase 4 study of Atrial Fibrillation and Intracranial Hemorrhages, sponsored by Population Health Research Institute.
- Active
- Registry status
- Phase 4
- Development phase
- 948
- Enrollment target
- 20
- Study locations
NCT03950076 is a Phase 4 study of Atrial Fibrillation and Intracranial Hemorrhages that is active but no longer recruiting, run by Population Health Research Institute. The registered enrollment target is 948 participants, below the 2,992-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03950076, a Phase 4 study of Atrial Fibrillation and Intracranial Hemorrhages, is active but no longer recruiting, sponsored by Population Health Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 948 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) or systemic embolism in high-risk atrial fibrillation (CHA2DS2-VASc ≥2) patients with previous intracranial hemorrhage.
Conditions Studied
Interventions
- DRUG Edoxaban
- OTHER Non-anticoagulant medical therapy
Study Locations (20)
Other
- Stat Research S.A. - Buenos Aires
- Hospital Italiano de Buenos Aires - Buenos Aires
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) - Buenos Aires
- Hospital Policial Churruca-Visca - Buenos Aires
- Centro Instituto Neurologico Salta - Salta
- Medical University of Innsbruck - Innsbruck
- Institut für Akutneurologie und Stroke Unit (IANS), Landeskrankenhaus Feldkirch - Rankweil
- Medical University of Vienna, Dept. of Neurology - Vienna
- Salzkammergutklinikum Vöcklabruck - Vöcklabruck
- Erasme Hospital - Brussels
Texas
- The University of Texas at Austin, Dell Medical School - Austin
- Texas Tech University Health Sciences Center at El Paso - El Paso
- Baylor St. Luke's Medical Center - Houston
Illinois
- Alexian Brothers Medical Center - Elk Grove Village
- Presence Care Transformation Corporation - Lisle
Pennsylvania
- The Hospital of the University of Pennsylvania - Philadelphia
- Allegheny General Hospital - Pittsburgh
Louisiana
- Tulane University Medical Center - New Orleans
New York
- New York Presbyterian - Queens - Queens
Washington
- MultiCare Institute for Research & Innovation - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 948 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2026-05-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03950076
The ClinicalTrials.gov registry entry for NCT03950076 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 948 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,992-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (68% lower). The listed sponsor is Population Health Research Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Edoxaban is the first listed.
NCT03950076 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT03950076 about?
NCT03950076 is a clinical study titled "EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)". To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) or systemic embolism in high-risk atrial fibrillation (CHA2...
What is the current status of trial NCT03950076?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 948 participants. The study started on 2019-09-20. Estimated completion is 2026-05-13.
What conditions does trial NCT03950076 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Intracranial Hemorrhages.
What interventions are being tested in trial NCT03950076?
The interventions under investigation include: Edoxaban (DRUG), Non-anticoagulant medical therapy (OTHER).
Who is sponsoring clinical trial NCT03950076?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03950076 being conducted?
This trial has 20 study locations across Illinois, Louisiana, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
-
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.